Human Cell-Based Disease Modeling
Creative Biolabs provides customizable human motor neuron model services for ALS and neuromuscular disease studies, supporting mechanism research, disease-phenotype characterization, target validation, and compound evaluation through model planning, cell culture, experimental execution, quantitative analysis, and scientific collaboration.
Scientific Rationale
Motor neurons integrate electrical activity, long-distance axonal transport, synaptic signaling, and interaction with skeletal muscle. Their selective dysfunction is central to ALS, while related neuromuscular disorders may involve motor-neuron survival, axon maintenance, peripheral connectivity, or communication at the neuromuscular junction.
Human iPSC-derived systems enable disease-associated genotypes to be investigated in a relevant cell type and can be paired with healthy, engineered, or gene-corrected comparators. Because differentiation state, culture age, cellular composition, and assay timing can materially affect the observed phenotype, model design should begin with the biological question and the decision the data must support.
Neurost also provides related iPSC-derived neural models, ALS cell models, and custom CNS disease modeling services for programs that extend beyond a motor-neuron-only design.
Configurable Platforms
The most informative format depends on whether the study prioritizes cell-autonomous mechanisms, genotype-specific comparison, temporal functional change, non-cell-autonomous effects, or motor neuron–muscle communication.
Model disease-associated genetic backgrounds in a human neuronal context. Programs may compare multiple patient and control lines to address biological heterogeneity where suitable cells and supporting documentation are available.
A controlled format for cell identity, survival, neurite architecture, protein localization, stress-response, and neuronal-function endpoints. It is well suited to mechanistic studies and assay-development work centered on motor-neuron-autonomous biology.
Motor neurons may be combined with supporting neural cells or skeletal-muscle components when the study requires non-cell-autonomous biology, axon-to-muscle connectivity, synaptic organization, or contraction-linked observations. Feasibility is assessed for each cell combination.
Not sure which model fits? Share the genotype, mechanism, comparator strategy, and intended decision point. The technical team can map these needs to a practical study design.
Plan a ModelFit-for-Purpose Phenotyping
A modular readout plan can combine orthogonal measures of model identity, cellular health, disease biology, and function. Exact assays and acceptance criteria are selected after feasibility review.
| Study Dimension | Potential Readouts | Research Value |
|---|---|---|
| Identity and culture quality | Motor-neuron and neuronal marker expression, morphology, culture composition, viability | Confirms that downstream phenotypes are interpreted in an appropriate cellular context |
| Neuronal function | Calcium dynamics, spontaneous or evoked activity, excitability-oriented measurements | Detects functional changes that may precede overt cell loss |
| Axon and neurite biology | Neurite length and branching, axonal integrity, organelle transport, cytoskeletal markers | Supports investigation of distal vulnerability and transport-related mechanisms |
| Disease pathology | Protein localization or aggregation, cellular stress, RNA-associated or genotype-linked phenotypes | Connects a disease mechanism to measurable cell-level endpoints |
| Therapeutic response | Dose response, phenotype rescue, toxicity counterscreens, confirmatory endpoints | Distinguishes apparent activity from general cytotoxicity and supports candidate prioritization |
Relevant assay capabilities can be explored through Neurost's neuronal MEA measurement, calcium assay, and high-content screening service pages.
Project Path
Align the disease context, genotype, mechanism, test articles, study scale, and the decision the results must support.
Review cell provenance and choose patient, healthy, engineered, or gene-corrected lines together with the culture format and controls.
Establish identity, culture quality, endpoint feasibility, sampling windows, and a reproducible assay window before the primary study.
Run the agreed conditions and replicates with project-specific controls, documented observations, and quality checks.
Provide organized data, methods, quality-control context, and a scientific summary suitable for internal review and next-step planning.
Research Use Cases
Investigate genotype-linked changes in protein homeostasis, RNA biology, excitability, stress responses, axonal maintenance, or cell survival.
Test whether genetic or pharmacological perturbation shifts a disease-relevant phenotype in an appropriate human cellular context.
Assess focused candidate sets or support assay development for phenotypic screening, including viability and mechanism-relevant counterscreens.
Follow time-dependent changes in neuronal activity, morphology, transport, or survival when disease features evolve with culture age.
Examine motor neuron–muscle connectivity and downstream functional consequences in a co-culture or NMJ-oriented system where technically feasible.
Adapt the framework for spinal muscular atrophy, Charcot-Marie-Tooth disease, or other motor-system disorders.
Collaboration
Engagement may begin with feasibility planning, proceed through a pilot, or cover an end-to-end model and assay study. Scope is matched to the maturity of your program.
Evidence Context
The following peer-reviewed studies illustrate why human motor-neuron models benefit from genotype-aware comparators, longitudinal functional measurements, and multicellular neuromuscular formats. These publications are independent research and are not presented as Neurost performance data.
Devlin and colleagues reported time-dependent changes in iPSC-derived motor neurons carrying TARDBP or C9orf72 ALS mutations, including an early hyperexcitable phase followed by reduced action-potential output and synaptic activity. The work supports sampling functional phenotypes across time rather than relying on a single terminal viability measurement.
Devlin, Anna-Claire, et al. “Human iPSC-Derived Motoneurons Harbouring TARDBP or C9ORF72 ALS Mutations Are Dysfunctional Despite Maintaining Viability.” Nature Communications, vol. 6, 2015, article 5999. https://doi.org/10.1038/ncomms6999
Guo and colleagues used FUS-ALS patient-derived motor neurons and a CRISPR-corrected isogenic line to connect mutant FUS with cytoplasmic pathology and progressive axonal-transport defects. This study is directly relevant to comparator design, transport assays, and phenotype-rescue experiments.
Guo, Wenting, et al. “HDAC6 Inhibition Reverses Axonal Transport Defects in Motor Neurons Derived from FUS-ALS Patients.” Nature Communications, vol. 8, 2017, article 861. https://doi.org/10.1038/s41467-017-00911-y
Pereira and colleagues generated human sensorimotor organoids containing motor neurons, skeletal muscle, and other relevant cell types, then observed NMJ-associated abnormalities across patient-derived and engineered ALS lines. The study motivates model formats that connect motor-neuron state to muscle-facing functional endpoints.
Pereira, João D., et al. “Human Sensorimotor Organoids Derived from Healthy and Amyotrophic Lateral Sclerosis Stem Cells Form Neuromuscular Junctions.” Nature Communications, vol. 12, 2021, article 4744. https://doi.org/10.1038/s41467-021-24776-4
Fill out the form below, and our expert team will contact you to design your custom project and accelerate breakthrough innovations.
